[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628277":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":26,"locations":34,"responsibleParty":132,"collaborators":11,"id":134,"slug":11,"hasResults":135,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":11,"eligibilityCriteria":139,"healthyVolunteers":135,"sex":140,"minAge":141,"maxAge":11,"enrollmentInfo":142,"targetDuration":11,"studyType":145,"phases":146,"briefSummary":148,"conditions":149,"keywords":153,"overallStatus":159,"whyStopped":11,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Administration of Nivolumab + Relatlimab Fixed-Dose Combination (FDC)","EXPERIMENTAL",null,[13],"Drug: Nivolumab + Relatlimab",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Nivolumab + Relatlimab","Specified dose on specified days",[9],[21,22],"Relopduo","BMS-986213",[24],{"name":5,"affiliation":5,"role":25},"STUDY_DIRECTOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":11,"email":31},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":33,"role":29,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[35,50,62,75,87,99,111,123],{"facility":36,"status":11,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Local Institution - 0009","Navi Mumbai","Maharashtra","400614","India",{"type":42,"coordinates":43},"Point",[44,45],73.01582,19.03681,{"lat":45,"lon":44},[48],{"name":49,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0009",{"facility":51,"status":11,"city":52,"state":38,"zip":53,"country":40,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Local Institution - 0008","Pune","411017",{"type":42,"coordinates":55},[56,57],73.85535,18.51957,{"lat":57,"lon":56},[60],{"name":61,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0008",{"facility":63,"status":11,"city":64,"state":65,"zip":66,"country":40,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Local Institution - 0003","Bhubaneswar","Odisha","751007",{"type":42,"coordinates":68},[69,70],85.83385,20.27241,{"lat":70,"lon":69},[73],{"name":74,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0003",{"facility":76,"status":11,"city":77,"state":11,"zip":78,"country":40,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Local Institution - 0002","Chennai","600006",{"type":42,"coordinates":80},[81,82],80.27847,13.08784,{"lat":82,"lon":81},[85],{"name":86,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0002",{"facility":88,"status":11,"city":89,"state":11,"zip":90,"country":40,"cosmosGeoPoint":91,"geoPoint":95,"contacts":96},"Local Institution - 0006","Mumbai","400 012",{"type":42,"coordinates":92},[93,94],72.88261,19.07283,{"lat":94,"lon":93},[97],{"name":98,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0006",{"facility":100,"status":11,"city":101,"state":11,"zip":102,"country":40,"cosmosGeoPoint":103,"geoPoint":107,"contacts":108},"Local Institution - 0005","Nagpur","440001",{"type":42,"coordinates":104},[105,106],79.08491,21.14631,{"lat":106,"lon":105},[109],{"name":110,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0005",{"facility":112,"status":11,"city":113,"state":11,"zip":114,"country":40,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Local Institution - 0004","New Delhi","110029",{"type":42,"coordinates":116},[117,118],77.2148,28.62137,{"lat":118,"lon":117},[121],{"name":122,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0004",{"facility":124,"status":11,"city":113,"state":11,"zip":125,"country":40,"cosmosGeoPoint":126,"geoPoint":128,"contacts":129},"Local Institution - 0001","110085",{"type":42,"coordinates":127},[117,118],{"lat":118,"lon":117},[130],{"name":131,"role":29,"phone":11,"phoneExt":11,"email":11},"Site 0001",{"type":133,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100628277",false,"NCT07459543","A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India","A Phase 4, Single Arm, Open Label Study to Evaluate Safety, Tolerability, and Efficacy of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in Participants With Previously Untreated, Unresectable or Metastatic Melanoma in India.","Inclusion Criteria\n\n* Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1\u002FLansky Performance Score ≥ 80% for minors (ages 12-17) ONLY.\n* Participants must have histologically confirmed Stage III (unresectable) or Stage IV melanoma, per the American Joint Committee on Cancer (AJCC) staging system (8th edition).\n* Participants must be treatment-naïve (ie, no prior systemic anticancer therapy for unresectable or metastatic melanoma).\n* Participants must have measurable disease by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.\n* Participants must have completed prior radiotherapy at least 2 weeks prior to study treatment administration.\n* Individuals of Childbearing Potential (IOCBP) must not be pregnant or breastfeeding.\n\nExclusion Criteria\n\n* Participants must not have active brain metastases or leptomeningeal metastases.\n* Participants must not have uveal melanoma.\n* Participants must not have an active, known, or suspected autoimmune disease.\n* Participants must not have a condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment.\n* Participants must not have a history of myocarditis.\n* Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways. Prior treatment with relatlimab or any other with LAG-3 targeted agents.\n* Other protocol-defined Inclusion\u002FExclusion criteria apply.","ALL","12 Years",{"count":143,"type":144},30,"ESTIMATED","INTERVENTIONAL",[147],"PHASE4","The purpose of this study is to assess the safety and tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) in untreated, unresectable or metastatic melanoma participants in India",[150,151,152],"Untreated Melanoma","Unresectable Melanoma","Metastatic Melanoma",[154,155,156,40,157,158],"Skin Cancer","Malignant Melanoma","Immunotherapy","Nivolumab","Relatlimab","NOT_YET_RECRUITING","2026-03-05",{"date":162,"type":163},"2026-03-09","ACTUAL",{"date":165,"type":144},"2026-11-15",{"date":167,"type":144},"2029-05-28",{"name":5,"class":6},8]